Antidepressant fluvoxamine can save Covid-19 patients, McMaster research shows
brighterworld.mcmaster.ca
brighterworld.mcmaster.ca
https://twitter.com/patrickc/status/1427367934880469010
n=1,472 patients; ~1/3 reduction in hospitalization; now pursuing a larger scale trial to replicate the results
The actual research results are here:
https://www.frontiersin.org/articles/10.3389/fphar.2021.6526...
From the paper, dosage in the trial was:
" Participants received 50 mg FLV QD on day 1, then for 2 days 100 mg FLV BID, and then 100 mg FLV TID as tolerated through day 15 and then stopped. "
Fluvoxamine has been long off patent. Based on my slap-dash googling of online pharmacies, this treatment would cost under US$10 total.
The hypothesized mechanisms of action are the anti-inflammatory, anti-platelet, and potentially antiviral activities which are side effects of Fluvoxamine's psychoactive properties. These mechanisms would counter some of the more serious body responses to the more severe cases of covid.
https://www.togethertrial.com/
I'm going to be skeptical until the paper comes out. There was a lot of initial data on Hydroxychloroquine that looked good and it ended up being only noise (and bad study designs).
They are late to the party, fluvoxamine and it's effects on Covid was already investigated and published by a team at Washington University in St Louis a last year in JAMA [0]
It's not the only medicine that has a potential effect on Covid-19 infection. Colchicine [1] for instance.
I should have done the research beforehand to know that the medication has the potential to make worse the symptoms it is supposed to remedy.
In the end, therapy did way more for me than those pills ever did.
I tried to find it and I found a much more recent study: https://www.nature.com/articles/s41380-021-01021-4#:~:text=I...
I had seen the original much earlier in the pandemic. There might be a link.
Actually many front-line doctors have been using a multidrug treatment based on existing medicines to successfully reduce hospitalization and death since very early on in the pandemic. One key aspect is treating patients early in the symptomatic phase with a combination of antiviral, corticosteroid, and antithrombotic medications. [1][2][3][4][5][6][7][8][9][10]
Many clinical trials have evaluated the suggested drugs in a single-drug treatment regime, but very few clinical trials have evaluated a multidrug treatment approach specifically focused on patients who are early in the symptomatic phase.
[1] Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection https://www.amjmed.com/article/S0002-9343(20)30673-2/fulltex...
[2] Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19) https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?a...
[3] Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection https://rcm.imrpress.com/EN/article/downloadArticleFile.do?a...
[4] Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents https://www.sciencedirect.com/science/article/abs/pii/S03069...
[5] Multidrug treatment for COVID-19 https://www.jstage.jst.go.jp/article/ddt/advpub/0/advpub_202...
[6] A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237953/
[7] Clofazimine broadly inhibits coronaviruses including SARS-CoV-2 https://www.nature.com/articles/s41586-021-03431-4
[8] In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2’s Main Protease https://pubs.acs.org/doi/pdf/10.1021/acs.jpclett.0c00994
[9] Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2 https://pubs.acs.org/doi/full/10.1021/acsmedchemlett.0c00521
[10] Repurposed Drugs, Molecular Vaccines, Immune‐Modulators, and Nanotherapeutics to Treat and Prevent COVID‐19 Associated with SARS‐CoV‐2, a Deadly Nanovector https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645867/
It's a tough call. I really want to support science and probably some combination of drugs in the above studies work. It's just hard to know which ones.
Related: https://www.thelancet.com/journals/lancet/article/PIIS0140-6...
Agreed, and thanks for the reference. Here are some promising results from a well designed and recently completed RCT evaluating Ivermectin in combination with doxycycline [1].
[1] Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial https://pubmed.ncbi.nlm.nih.gov/33983065/
I don’t know how useful drugs are that have to be used in the early symptom phase. Does this require everybody to present themselves to a doctor every time they get upper respiratory symptoms?